Cargando…
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Compuscript
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832958/ https://www.ncbi.nlm.nih.gov/pubmed/34708999 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520 |